A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced ER-Positive HER2-Negative Breast Cancer
Interventions: DRUG: AZD9833|DRUG: Fulvestrant
Sponsor: AstraZeneca